Abstract
The revision of various guidelines and standards in various countries has diversified the diagnosis and treatment mode of thyroid cancer, giving rise to many doubts and discussions about the related issues. Among them, the excessive and under diagnosis and treatment is the subject of endless debate. Based on the current changes in the diagnosis and treatment of thyroid cancer, this short communication expounds my personal views on the excessive and under diagnosis and treatment of thyroid cancer.
Reference10 articles.
1. Jin s. Advances in Thyroid Diseases, 1th edn. Liaoning Science and Technology Publishing House, Shenyang, 2021
2. Sugitani I. Active surveillance of low-risk papillary thyroid microcarcinoma. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101630. [PMID: 35256266 DOI: 10.1016/j.beem.2022.101630]
3. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol 2016;2:1023-1029. [PMID: 27078145 DOI: 10.1001/jamaoncol.2016.0386]
4. Bychkov A, Keelawat S, Agarwal S, et al. Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries. Pathology. 2018;50:411-417. [PMID: 29631726 DOI: 10.1016/j.pathol.2017.11.088]
5. Jin s. General Rules for the Description of Thyroid Cancer, 8th edn. Liaoning Science and Technology Publishing House, Shenyang, 2021